Short answer
Spero Therapeutics Inc (SPRO) filed its Q2 2019 10-Q quarterly report on Aug 8, 2019 for the quarter ended Jun 30, 2019.
Spero Therapeutics Inc Q2 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $2.156M, up from $1.693M YoY, driven primarily by BARDA grant funding
- Net loss $13.150M vs $9.956M YoY, operating loss $13.652M vs $9.971M
- Best program: SPR994 R&D $6.893M, up $5.111M YoY; Potentiator Platform down $1.892M
- Cash, equivalents and marketable securities $103.4M; operating cash use $23.0M for six months
- Funding expected through second half of 2020, including SPR994 Phase 3 top-line readout; substantial additional funding required thereafter
Risk Factors
- Funding runway into second half of 2020, including SPR994 Phase 3 readout, based on June 30, 2019 resources
- BARDA funding increased $2.5 million to $18.1 million in May 2019, with remaining award subject to two options
- SPR994 Phase 3 risk: prior Japanese Phase 2 trials differed from FDA cUTI guidance, potentially requiring delays or additional costs
- GDPR noncompliance exposure: fines up to €20 million or 4% of annual global revenues
- Manufacturing concentration: small number of third-party suppliers without long-term agreements for clinical materials
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Spero Therapeutics Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.